ADSB-FUB-187 is an
indazole
Indazole, also called isoindazole, is a heterocyclic aromatic organic compound. This bicyclic compound consists of the fusion of benzene and pyrazole.
Indazole is an amphoteric molecule which can be protonated to an indazolium cation or deproton ...
-based
synthetic cannabinoid. It is a potent
agonist of the
CB1 receptor with a
binding affinity
In biochemistry and pharmacology, a ligand is a substance that forms a complex with a biomolecule to serve a biological purpose. The etymology stems from ''ligare'', which means 'to bind'. In protein-ligand binding, the ligand is usually a m ...
of ''K''
i = 0.09 nM and an
EC50 of 1.09 nM.
It was originally developed by
Pfizer
Pfizer Inc. ( ) is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer ...
in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of ''K''
i, it is not the most potent compound at producing a CB
1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC
50 values.
Legality
Sweden's public health agency suggested classifying ADSB-FUB-187 as hazardous substance on November 10, 2014, following its use as an ingredient in grey-market
synthetic cannabis products.
See also
*
AB-FUBINACA
AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with ''K''i values of 0.9 nM at CB1 and 23.2 nM at CB2 and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. It was originally developed by P ...
*
ADB-FUBINACA
References
Cannabinoids
Designer drugs
Indazolecarboxamides
Fluoroarenes
{{cannabinoid-stub